nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

24.08.2016 | Meeting Report

The fifteenth International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6–8 October 2015, Tübingen, Germany: looking back on 15 years of progress

verfasst von: Christopher Shipp, Graham Pawelec

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

PIVAC-15, held 6–8 October 2015 in Tübingen, Germany, marked the 15th anniversary of the PIVAC conference series (http://www.tati-group.de/pivac), held every year since PIVAC-1 in 2001 in Cambridge, UK. Prominent themes covered during the 2015 PIVAC meeting included therapies which can be used to modulate the immune system or reduce tumour-induced immune suppression, the selection of more appropriate immunotherapy targets, and methods that can be used to improve antigen presentation. In the context of 15 years of “Progress in Vaccination against Cancer”, speakers were asked to consider vaccination in the era of immunomodulatory antibody therapies that have so revolutionised the treatment of several types of cancer over the last few years. …

Titel: The fifteenth International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6–8 October 2015, Tübingen, Germany: looking back on 15 years of progress
verfasst von: Christopher Shipp
Graham Pawelec
Publikationsdatum: 24.08.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2017
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-016-1888-4

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The fifteenth International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6–8 October 2015, Tübingen, Germany: looking back on 15 years of progress

Excerpt

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Designing therapeutic cancer vaccines by mimicking viral infections

Immunosenescence: limitations of natural killer cell-based cancer immunotherapy

Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies

Cytokine-induced killer cells hunt individual cancer cells in droves in a mouse model

Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer

Rejection versus escape: the tumor MHC dilemma

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie